Jean‐claude Bystryn
#147,633
Most Influential Person Now
Jean‐claude Bystryn's AcademicInfluence.com Rankings
Jean‐claude Bystrynphilosophy Degrees
Philosophy
#8013
World Rank
#11312
Historical Rank
Logic
#5052
World Rank
#6411
Historical Rank
Download Badge
Philosophy
Jean‐claude Bystryn's Degrees
- Doctorate Medicine Université Paris Cité
Why Is Jean‐claude Bystryn Influential?
(Suggest an Edit or Addition)Jean‐claude Bystryn's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. (2008) (465)
- The adjuvant therapy of pemphigus. An update. (1996) (295)
- Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts. (2012) (274)
- Adjuvant therapy of pemphigus. (1984) (240)
- Prognostic significance of hypopigmentation in malignant melanoma. (1987) (229)
- Antibodies to normal human melanocytes in vitiligo (1983) (211)
- Evidence for immunologic mechanisms in human vitiligo: patients' sera induce damage to human melanocytes in vitro by complement-mediated damage and antibody-dependent cellular cytotoxicity. (1988) (190)
- Reliability and convergent validity of two outcome instruments for pemphigus. (2009) (184)
- Serum levels of circulating intercellular adhesion molecule 1 in human malignant melanoma. (1991) (183)
- Patterns of remission in pemphigus vulgaris. (2000) (182)
- Relation between the incidence and level of pigment cell antibodies and disease activity in vitiligo. (1991) (179)
- REGULATION OF ANTIBODY FORMATION BY SERUM ANTIBODY : II. REMOVAL OF SPECIFIC ANTIBODY BY MEANS OF EXCHANGE TRANSFUSION (1970) (146)
- Correlation between vitiligo antibodies and extent of depigmentation in vitiligo. (1986) (145)
- Detection of antibodies to melanocytes in vitiligo by specific immunoprecipitation. (1983) (134)
- Different populations of melanocytes are present in hair follicles and epidermis. (1996) (131)
- Antibodies to hair follicles in alopecia areata. (1994) (126)
- Apoptolysis: a novel mechanism of skin blistering in pemphigus vulgaris linking the apoptotic pathways to basal cell shrinkage and suprabasal acantholysis (2009) (125)
- Regional variation in the expression of pemphigus foliaceus, pemphigus erythematosus, and pemphigus vulgaris antigens in human skin. (1991) (112)
- Ineffectiveness of cyclosporine as an adjuvant to corticosteroids in the treatment of pemphigus. (2000) (108)
- Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine. (2001) (108)
- Melanoma and vitiligo are associated with antibody responses to similar antigens on pigment cells. (1995) (104)
- Identification of pigment cell antigens defined by vitiligo antibodies. (1992) (103)
- Are desmoglein autoantibodies essential for the immunopathogenesis of pemphigus vulgaris, or just ‘witnesses of disease'? (2006) (101)
- Cytolytic antibodies to melanocytes in vitiligo. (1993) (96)
- Relationship between immune response to melanoma vaccine immunization and clinical outcome in stage II malignant melanoma (2010) (94)
- HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients. (1998) (89)
- Effect of plasmapheresis therapy on circulating levels of pemphigus antibodies. (1990) (84)
- Hair follicle structures targeted by antibodies in patients with alopecia areata. (1997) (80)
- A Model for the Regulation of Antibody Synthesis by Serum Antibody (1971) (79)
- Tumid lupus erythematosus: criteria for classification with immunohistochemical analysis. (2003) (76)
- Comparison of Alopecia areata in Human and Nonhuman Mammalian Species (1998) (76)
- Substrate specificity of anti-epithelial antibodies of pemphigus vulgaris and pemphigus foliaceus sera in immunofluorescence tests on monkey and guinea pig esophagus sections. (1987) (76)
- Plasmapheresis and immunosuppressive therapy. Effect on levels of intercellular antibodies in pemphigus vulgaris. (1979) (76)
- Autoantibodies to hair follicles in C3H/HeJ mice with alopecia areata-like hair loss. (1997) (74)
- Antibodies to desmoglein 1 and 3, and the clinical phenotype of pemphigus vulgaris. (2003) (72)
- Changes in the presence of multiple markers of circulating melanoma cells correlate with clinical outcome in patients with melanoma. (2003) (70)
- Isolation and long-term culture of human hair-follicle melanocytes. (1995) (70)
- Laryngeal and nasal involvement in pemphigus vulgaris. (2001) (66)
- A novel explanation for acantholysis in pemphigus vulgaris: the basal cell shrinkage hypothesis. (2006) (64)
- Improved survival of patients with melanoma with an antibody response to immunization to a polyvalent melanoma vaccine (1995) (64)
- Topical imiquimod is a potent adjuvant to a weakly-immunogenic protein prototype vaccine. (2006) (62)
- Serum antibodies in vitiligo patients. (1989) (61)
- Antibodies against the cytoplasm of human epidermal cells. (1973) (60)
- Heterogeneity of pemphigoid antigens. (1983) (59)
- Antibodies to melanocytes. Occurrence in patients with vitiligo and chronic mucocutaneous candidiasis. (1981) (59)
- Direct immunofluorescence studies in alopecia areata and male pattern alopecia. (1979) (56)
- CDKN2A mutations in multiple primary melanomas. (1998) (56)
- Immunogenicity of a polyvalent melanoma antigen vaccine in humans (1988) (56)
- THE SIGNIFICANCE OF VITILIGO ANTIBODIES (1985) (55)
- Enhanced Immunogenicity of Plasmodium falciparum Peptide Vaccines Using a Topical Adjuvant Containing a Potent Synthetic Toll-Like Receptor 7 Agonist, Imiquimod (2008) (55)
- Characterization of vitiligo antigens. (1995) (55)
- Methotrexate as an adjuvant treatment for pemphigus vulgaris. (1999) (55)
- Intravenous immunoglobulin in the treatment of autoimmune bullous dermatoses: An update (2012) (54)
- Immune mechanisms in vitiligo. (1997) (54)
- Antibody response and tumor growth in syngeneic mice immunized to partially purified B16 melanoma-associated antigens. (1978) (54)
- Pemphigus foliaceus. Subcorneal intercellular antibodies of unique specificity. (1974) (53)
- IVIg selectively and rapidly decreases circulating pathogenic autoantibodies in pemphigus vulgaris (2006) (51)
- Antibodies to Surface Antigens of Pigmented Cells in Animals with Vitiligo 1 (1986) (51)
- The change of melanocyte cytotoxicity after systemic steroid treatment in vitiligo patients. (1993) (50)
- Identification and solubilization of iodinated cell surface human melanoma associated antigens (1977) (50)
- Treatment of pemphigus with intravenous immunoglobulin. (2002) (50)
- Enhanced Susceptibility of Melanocytes to Different Immunologic Effector Mechanisms In Vitro: Potential Mechanisms for Postinflammatory Hypopigmentation and Vitiligo (1988) (49)
- Sensitivity of indirect immunofluorescence, substrate specificity, and immunoblotting in the diagnosis of pemphigus. (1997) (49)
- Preparation and characterization of a polyvalent human melanoma antigen vaccine. (1986) (46)
- Vaccine-induced CD8+ T-cell responses to MAGE-3 correlate with clinical outcome in patients with melanoma. (2003) (45)
- Absence of intercellular antigens in the deep layers of the epidermis in pemphigus foliaceus. (1978) (45)
- Regional variation in the expression of bullous pemphigoid antigen and location of lesions in bullous pemphigoid. (1984) (45)
- TLR7 imidazoquinoline ligand 3M-019 is a potent adjuvant for pure protein prototype vaccines (2007) (45)
- Regional variations in antigenic properties of skin. A possible cause for disease-specific distribution of skin lesions (1986) (45)
- Plasmapheresis therapy of pemphigus. (1988) (44)
- Pemphigus (2005) (44)
- Effect of DETOX as an adjuvant for melanoma vaccine. (1995) (43)
- Oral psoralen with UV-A therapy releases circulating growth factor(s) that stimulates cell proliferation. (1997) (42)
- Release of Cell-Surface Tumor-Associated Antigens by Viable Melanoma Cells From Humans (1977) (40)
- Effect of intravenous immunoglobulin therapy on serum levels of IgG1 and IgG4 antidesmoglein 1 and antidesmoglein 3 antibodies in pemphigus vulgaris. (2008) (40)
- Epidermal cytoplasmic antibodies: incidence and type in normal persons and patients with melanoma. (1976) (39)
- Release of tumor-associated antigens by murine melanoma cells. (1976) (39)
- Identification of immunogenic human melanoma antigens in a polyvalent melanoma vaccine. (1992) (38)
- Expression of SS-A/Ro and SS-B/La antigens in skin biopsy specimens of patients with photosensitive forms of lupus erythematosus. (2000) (38)
- Autoimmune diseases of the skin. (1989) (37)
- Total leucoderma: a rare manifestation of cutaneous chronic graft-versus-host disease. (1996) (37)
- Partial isolation and characterization of antigen(s) associated with murine melanoma. (1974) (36)
- Improved identification of potentially dangerous pigmented skin lesions by computerized image analysis. (2003) (35)
- Immunogenicity and Clinical Activity of a Polyvalent Melanoma Antigen Vaccine Prepared from Shed Antigens a (1993) (35)
- Antimelanoma antibodies in swine with spontaneously regressing melanoma. (1995) (34)
- BINDING OF ANTIGEN BY IMMUNOCYTES : I. EFFECT OF LIGAND VALENCE ON BINDING AFFINITY OF MOPC 315 CELLS FOR DNP CONJUGATES (1973) (33)
- Epidermal cytoplasmic antigens: II. Concurrent presence of antigens of different specificities in normal human skin. (1978) (33)
- Identification of cicatricial pemphigoid antigens. (1992) (32)
- Intravenous immunoglobulin selectively decreases circulating autoantibodies in pemphigus. (2008) (32)
- Immunologic aspects of hair loss. (1991) (31)
- IVI g TREATMENT OF PEMPHIGUS: how it works and how to use it. (2005) (31)
- Vitiligo antibodies are not directed to tyrosinase. (1999) (31)
- Epidermolysis bullosa acquisita. Incidence in patients with basement membrane zone antibodies. (1990) (31)
- Specific Immunotherapy of Cancer With Vaccines (1993) (30)
- Tumor vaccines (2004) (29)
- Comparison of cell-surface human melanoma-associated antigens identified by rabbit and murine antibodies. (1982) (29)
- A paraneoplastic mixed bullous skin disease associated with anti-skin antibodies and a B-cell lymphoma. (1993) (29)
- Effect of intravenous immunoglobulin with or without cytotoxic drugs on pemphigus intercellular antibodies. (2011) (27)
- Identification of HLA-A*03, A*11 and B*07-restricted melanoma-associated peptides that are immunogenic in vivo by vaccine-induced immune response (VIIR) analysis. (2000) (27)
- Immunofluorescence abnormalities in lichen planopilaris. (1992) (26)
- Identification of a 160-kD molecule as a component of the basement membrane zone and as a minor bullous pemphigoid antigen. (1990) (26)
- Dermoscopic and histopathologic diagnosis of equivocal melanocytic skin lesions (2003) (25)
- Immunofluorescence studies in transient acantholytic dermatosis (Grover's disease). (1979) (25)
- Improvement of intravenous immunoglobulin therapy for bullous pemphigoid by adding immunosuppressive agents: marked improvement in depletion of circulating autoantibodies. (2008) (25)
- Clinical significance of basal cell layer antibodies. (1977) (25)
- Lack of effect of cyclophosphamide on the immunogenicity of a melanoma antigen vaccine. (1991) (23)
- Growth and immunogenicity of murine B-16 melanoma. (1974) (23)
- Identification and purification of a Mr 75,000 cell surface human melanoma-associated antigen. (1982) (22)
- Release of surface macromolecules by human melanoma and normal cells. (1981) (22)
- Clinical activity of a polyvalent melanoma antigen vaccine. (1995) (22)
- Why is the mortality of bullous pemphigoid greater in Europe than in the US? (2005) (22)
- Potential role of interleukin-17 in the pathogenesis of bullous pemphigoid. (2010) (22)
- Epidermolysis Bullosa Acquisita: Incidence in Patients With Basement Membrane Zone Antibodies (1990) (21)
- An improved europium release assay for complement-mediated cytolysis. (1992) (21)
- Sepcific removal of in vivo antibody by extracorporeal circulation over an immunoadsorbent in gel. (1971) (20)
- Limitations in enzyme-linked immunosorbent assays for antibodies against desmogleins 1 and 3 in patients with pemphigus. (2002) (20)
- A novel bullous pemphigoid antigen (BP125) located in the deeper layers of the basement membrane zone. (1994) (20)
- Alterations in antigenic properties of normal epidermis adjacent to basal cell carcinomas. (1981) (20)
- Epiluminescence microscopy: a reevaluation of its purpose. (2001) (19)
- Identification of melanoma antigens that are immunogenic in humans and expressed in vivo. (1998) (19)
- Cytoplasmic differentiation antigens of human epidermal cells. (1979) (18)
- Anti-pigment-cell factors and mucocutaneous candidiasis. (1981) (18)
- Sensitivity of indirect immunofluorescence and ELISA in detecting intercellular antibodies in endemic pemphigus foliaceus (Fogo Selvagem) (2006) (18)
- Antibodies to desmoplakin in a patient with pemphigus foliaceous (1998) (18)
- Purification and partial characterization of a murine melanoma-associated antigen. (1980) (18)
- Interleukin-2/liposomes potentiate immune responses to a soluble protein cancer vaccine in mice (2006) (17)
- Response to: Circulating Tumor Cells and Detection of Melanoma-Associated Antigen HMW-MAA in the Serum of Melanoma Patients (2006) (17)
- Vaccines for melanoma. Design strategies and clinical results. (1998) (17)
- Heterogeneity in the expression of Ro and La antigens in human skin. (1995) (17)
- Variability of the lupus band test. Results in 18 patients with systemic lupus erythematosus. (1983) (17)
- Dermatology manpower needs. (2000) (17)
- The Immunobiology of Human Malignant Melanoma (1980) (17)
- Induction of B16 melanoma melanogenesis by a serum-free synthetic medium. (1992) (16)
- Autoantibodies to hair follicles in normal individuals. (1994) (16)
- Effect of substrate on indirect immunofluorescence tests for intercellular and basement membrane zone antibodies. (1986) (16)
- Effect of cell wall skeleton and monophosphoryl lipid A adjuvant on the immunogenicity of a murine B16 melanoma vaccine. (1991) (16)
- Induction of tumor-infiltrating lymphocytes in human malignant melanoma metastases by immunization to melanoma antigen vaccine. (1989) (15)
- Skin biopsies in the evaluation of atypical optic neuropathies. (1993) (14)
- Immunophenotype of human melanoma cells in different metastases. (1985) (14)
- Cytoplasmic melanoma‐associated antigen (CYT‐MAA) serum level in patients with melanoma: A potential marker of response to immunotherapy? (2006) (14)
- Heterogeneity of pemphigus vulgaris antigens. (1987) (14)
- Pemphigus foliaceus associated with absence of intercellular antigens in lower layers of epidermis. (1977) (14)
- Detection of immunoglobulin G antibodies in melanoma sera reactive with intracellular proteins. (1988) (14)
- Detection of antibodies to melanocytes in vitiligo by western immunoblotting. (1996) (13)
- Immunity to hair follicles in alopecia areata. (1995) (13)
- Atypical herpes simplex can mimic a flare of disease activity in patients with pemphigus vulgaris (1999) (12)
- Identification of basement membrane zone antigens defined by antibodies that react to both the epidermal and dermal side of 1 M sodium chloride split skin. (1991) (12)
- Immunosurveillance and melanoma. (1989) (12)
- Clearance of iodoantipyrene from methacholine blanched skin in atopics. (1969) (12)
- Relation between skin temperature and location of facial lesions in seborrheic dermatitis. (2000) (12)
- Association of tissue-fixed cytoplasmic deposits of immunoglobulin in epidermal keratinocytes with lupus erythematosus. (1993) (11)
- Pemphigus vulgaris with involvement of the cervix treated using thalidomide therapy (2004) (11)
- Decreased expression of epidermal cytoplasmic antigens in cultured human keratinocytes. (1981) (11)
- Systemic Steroids Suppress Antimelanocyte Antibodies in Vitiligo (1997) (11)
- Binding of antigen by immunocytes. II. Effect of specific Ig on antigen binding by MOPC 315 cells (1975) (10)
- Shedding and Degradation of Cell-Surface Macromolecules and Melanoma-Associated Antigens by Human Melanoma (1982) (10)
- Immunology and immunotherapy of human malignant melanoma. (1985) (10)
- Double-antibody radioimmunoassay for B16 melanoma antibodies. (1974) (10)
- Sensitivity of indirect immunofluorescence and immunoblotting for the detection of intercellular antibodies in endemic pemphigus foliaceus (fogo selvagem) (1999) (10)
- Comparative effectiveness of azathioprine or mycophenolate mofetil as an adjuvant for the treatment of bullous pemphigoid. (2008) (9)
- Theories on the Pathogenesis of Depigmentation: Immune Hypothesis (2008) (9)
- Heterogeneous antibody response to polyvalent melanoma vaccines in syngeneic mice (2005) (9)
- Erythema multiforme with mucous membrane involvement and Stevens-Johnson syndrome are clinically different disorders. (1996) (8)
- Degradation of tumor-associated antigens shed by human melanoma cells in culture. (1982) (8)
- Vaccines for melanoma. (1998) (8)
- Oral and topical corticosteroids in bullous pemphigoid. (2002) (8)
- Vitiligo and antibodies to melanocytes. (1988) (8)
- Molecular identification of major and minor bullous pemphigoid antigens. (1990) (8)
- Anti-trichohyalin antibodies in canine alopecia areata (1998) (8)
- Behcet's syndrome: an unusual cause of colonic ulceration and perforation. (1981) (8)
- Bullous pemphigoid antibodies. Human skin as a substrate for indirect immunofluorescence assay. (1985) (7)
- Kinetics of response to conventional treatment in patients with pemphigus vulgaris. (2008) (7)
- Autocatabolism of surface macromolecules shed by human melanoma cells. (1982) (7)
- Is mycophenolic acid effective for the treatment of pemphigus? (1999) (7)
- Erythema Multiforme With Mucous Membrane Involvement and Stevens-Johnson Syndrome Are Clinically Different Disorders (1996) (7)
- Circulating tumor cells and detection of the melanoma-associated antigen HMW-MAA in the serum of melanoma patients. Authors' reply (2006) (6)
- Expression of vitiligo antigen on a revertant line of hamster melanoma cells. (1984) (6)
- Serum levels of inhibitors of apoptotic proteins (IAPs) change with IVIg therapy in pemphigus. (2011) (6)
- Vitiligo-related pigment cell differentiation antigens are expressed on malignant melanoma cells following phenotypic reversion induced by contact inhibitory factor. (1985) (6)
- Emerging melanoma vaccines (2002) (6)
- The Regulation of Antibody Formation (1971) (6)
- Effect of tunicamycin on release of macromolecules and tumor antigens by human melanoma cells. (1985) (6)
- Identification of a novel basement membrane antigen (p84) defined by sera with antibodies to both the epidermal and dermal side of split skin. (1994) (6)
- Immunobiology of alopecia areata (2000) (5)
- Skin blood flow in atopic dermatitis. (1969) (5)
- Limitations in the diagnosis of vesiculobullous diseases (1983) (5)
- Melanoma vaccines: what we know so far. (2005) (5)
- How should pemphigus be treated? (2002) (5)
- Nonmelanoma skin cancer, melanomas, warts, and viral oncogenesis. (1984) (5)
- Use of vaccines in treatment of malignant melanoma. (1996) (5)
- Case reportAntibodies to desmoplakin in a patient with pemphigus foliaceous (1998) (5)
- Decrease in circulating tumor cells as an early marker of therapy effectiveness. (2001) (5)
- In vitro cell-mediated immune responses induced by a polyvalent allogeneic melanoma vaccine. (1995) (5)
- Total leucoderma: a rare manifestation of cutaneous chronic graft‐versus‐host disease (1996) (4)
- Does imiquimod work in infantile hemangiomas? (2007) (4)
- Relation between antibodies to BP180 and gender in bullous pemphigoid. (1999) (4)
- Mechanism of autodegradation of cell-surface macromolecules shed by human melanoma cells. (1984) (4)
- Vaccine Immunotherapy of Melanoma (1990) (4)
- BINDING OF ANTIGEN BY IMMUNOCYTES (1973) (3)
- Letter: Antiepithelial antibodies: a possible clue to malignant neoplasms. (1974) (3)
- Identification of immunogenic B16 melanoma-associated antigens. (1987) (3)
- Does adalimumab cause bullous pemphigoid? (2010) (3)
- Can nondermatologists really recognize potentially dangerous skin lesions as well as dermatologists? (2002) (3)
- Immunogenicity and tumor protective activity of B16 melanoma vaccines. (1989) (3)
- Pemphigus, pemphigoid, and epidermal upper-cytoplasmic antigens: Changes in expression in cultured human keratinocytes (2004) (3)
- Intercellular deposits of complement in skin of patients with pemphigus. (1981) (3)
- EPIDERMAL ANTIGENS (1977) (3)
- Differentiation and shedding of surface macromolecules of human keratinocytes. (1984) (3)
- Treatment options in pemphigus. (2009) (3)
- Depigmentation Other Than Vitiligo (2008) (3)
- Temperature and blood flow in macules of lepromatous leprosy. (1969) (3)
- Histologic Cutaneous Modifications After the Use of EMLA Cream, A Diagnostic Pitfall: Review of 13 Cases (2007) (2)
- Frequency of shifts over time in the profile of antidesmoglein antibodies in pemphigus vulgaris. (2007) (2)
- Natural Stratum Corneum Antibodies and Antigens (1983) (2)
- The cause of acantholysis in pemphigus: further support for the ‘basal cell shrinkage’ hypothesis (2009) (2)
- REGULATION OF ANTIBODY FORMATION BY SERUM ANTIBODY (1970) (2)
- Immunotherapy of malignant melanoma. (1991) (2)
- Antiepithelial Antibodies: A Possible Clue to Malignant Neoplasms-Reply (1974) (2)
- Vaccine-induced CD 8 T-cell Responses to MAGE-3 Correlate with Clinical Outcome in Patients with Melanoma 1 (2003) (2)
- Increasing ratio of thin to thick melanoma lesions: pathogenesis and early detection of this cancer. (2007) (2)
- Identification and purification of 115- and 125-kilodalton cell surface human melanoma-associated antigens. (1986) (2)
- An alternate explanation for the decrease in pemphigus antibodies with combination treatment of double-filtration plasmapheresis and IVIg. (2009) (2)
- Randomized, double-blind, clinical trial of a polyvalent melanoma vaccine in patients with stage III melanoma (1998) (2)
- Reproducibility of the immunofluorescent test for antimelanoma antibodies. (1976) (2)
- A confusing message will not improve the detection of melanoma. (2007) (1)
- Heterogeneity in CD8+ T cell responses to MAGE-3, Melan A/MART-1, GP100, tyrosinase, MSH and TRP-2 in vaccine-treated patients with melanoma (1998) (1)
- Identification of melanoma cell surface antigens immunogenic in mice. (1994) (1)
- A tribute to Bernie. (1994) (1)
- Emerging melanoma vaccines (2005) (1)
- Cutaneous pemphigus vulgaris: what causes it? (2006) (1)
- An alternate explanation for the increase in the incidence of melanoma being restricted to patients with thin lesions. (2000) (1)
- Evaluation and management of diseases of the vulva: bullous diseases. (1978) (1)
- Differentiation of pemphigus antibodies of the vulgaris and follaceus types on monkey and guinea pig esophagus sections. (1990) (1)
- Therapy of pemphigus. (1988) (1)
- Skin graft transfer of alopecia areata from affected to unaffected C3H/HeJ mice (1998) (0)
- A novel bullous pemphigoid antigen (BP125) is located in the deeper layers of the basement membrane zone (1993) (0)
- Basal Cell Layer Antibodies in Patients With Burns-Reply (1979) (0)
- Clinical activity of a polyvalent melanoma vaccine (1993) (0)
- Circulating Antibodies Reactive With Cytoplasmic Antigens of Upper and Germinal Cells of Human Skin-Reply (1978) (0)
- Reimbursement for evaluation and management services. (1999) (0)
- Skin Tumor Markers (1982) (0)
- Specificity and immunogenicity of antigens associated with murine melanoma. Abstr. (1975) (0)
- Expression of toxic epidermal necrolysis in grafted skin is donor-site dominant. (1993) (0)
- Stimulation of CD8+T cell responses to MAGE-3 and MART-1 by a shed, polyvalent melanoma antigen vaccine: 031 (1997) (0)
- Drug fever. (1972) (0)
- REPLY TO DR. SAURAT (1979) (0)
- IL-2 Liposomes markedly enhance the immunogenicity of a shed, polyvalent melanoma vaccine: 475 (1997) (0)
- Effect of methotrexate on the induction of remissions in pemphigus vulgaris (1998) (0)
- The expression of RO and LA antigens is increased in the skin of patients with photosensitive lupus erythematosus (1998) (0)
- Vitiligo Antigen in Melanoma Cells (1986) (0)
- Alopecia Areata, Bethesda MD, October 25-26, 1990 (1991) (0)
- Assay of peptide binding affinity to HLA-A * 0201 (1998) (0)
- Limitations of direct immunofluorescence. (1992) (0)
- Heterogeneity of Pemphigus (2017) (0)
- Clinically beneficial immune reponses to melanoma vaccine treatment: 104 (1993) (0)
- Normal individuals have antibodies to hair follicle antigens which are modulated during the hair growth cycle (1993) (0)
- Patent Number : 45 ) Date of Patent : 5 , 030 , 621 Jul . 9 , 1991 (2017) (0)
- Preface (1993) (0)
- Viewpoint 4 (2006) (0)
- NEOPLASMS Malignant: Release of cell‐surface tumorassociated antigens by viable melanoma cells from humans (1978) (0)
- Double-Blind Trial of a Polyvalent , Shed-Antigen , Melanoma Vaccine 1 (2001) (0)
- Immunopathology of the Skin: Labeled Antibody Studies (Book) (1975) (0)
- Release of tumor associated antigen(s) by murine melanoma cells. Abstr. (1976) (0)
- Improved survival of melanoma patients with antibody responses to a polyvalent melanoma vaccine (1993) (0)
- The problems with punitive damages in lawsuits against managed-care organizations. (2000) (0)
- Laryngeal and nasal involvement in pemphigus vulgaris (1998) (0)
- Immune mechanisms in vitiligo. (1989) (0)
- CONTACT UNRESPONSIVENESS IN CARCINOGEN INFUSED GUINEA PIGS (2010) (0)
- B I N D I N G OF A N T I G E N BY I M M U N O C Y T E S I. EFFECT OF LIGAND VALENCE ON BINDING A~FINIT¥ OF MOPC 315 CELLS (2003) (0)
This paper list is powered by the following services:
